Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for determining blood drug level of mizoribine

A blood drug concentration and mizoribine technology, applied in the field of medical testing, can solve the problems of unsuitable drug concentration monitoring, cumbersome and time-consuming operation, high analysis cost, etc., and achieve the effect of simple pretreatment method, less plasma consumption and high sensitivity

Inactive Publication Date: 2008-08-27
AFFILIATED HUSN HOSPITAL OF FUDAN UNIV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Existing technical methods have low sensitivity (lowest limit of quantification is 0.25mg L -1 ), cumbersome and time-consuming operation, low efficiency, high analysis cost and other defects, it is not suitable for routine therapeutic drug concentration monitoring

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for determining blood drug level of mizoribine
  • Method for determining blood drug level of mizoribine
  • Method for determining blood drug level of mizoribine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Chromatographic conditions

[0026] Column: Phenomenex Luna NH 2 (4.6mm×250mm, 5 μm, American Phenomenex Company); mobile phase: acetonitrile-methanol-0.1% trifluoroacetic acid (85:5:10); flow rate: 1.5mL min -1 ; Column temperature: 30°C; Detection wavelength, 280nm.

[0027] Plasma sample pretreatment

[0028] Take 100 μL of plasma sample, add 100 μL of acetonitrile solution, vortex mix for 20 s, centrifuge at 12000×g for 10 min at 4°C, and take 20 μL of supernatant for injection. The external standard method was used to quantify the peak area.

[0029] Exclusive

[0030] Blood samples from 10 kidney transplant patients who did not take MZR were taken from different sources, and measured according to the above sample pretreatment and measurement methods. The results showed that no endogenous substances were found to interfere with the above-mentioned components. The commonly used drug combination and non-prescription drug reference solution were injected. The res...

Embodiment 2

[0039] Chromatographic conditions

[0040] Column: Phenomenex Luna NH 2 (4.6mm×250mm, 5 μm, American Phenomenex Company); mobile phase: acetonitrile-methanol-0.1% trifluoroacetic acid (85:5:10); flow rate: 1.5mL min -1 ; Column temperature: 30°C; Detection wavelength, 280nm.

[0041] Plasma sample pretreatment

[0042] Take 100 μL of plasma sample, add 100 μL of a mixture of acetonitrile and methanol (1:1, v / v), vortex mix for 20 s, centrifuge at 12,000×g for 10 min at 4°C, and take 20 μL of supernatant for injection. The external standard method was used to quantify the peak area.

[0043] Exclusive

[0044] Blood samples were taken from 10 kidney transplant patients who did not take MZR, and were determined according to the above-mentioned sample pretreatment and determination methods. In addition, commonly used drug combination and over-the-counter drug reference solution were injected. Results showed endogenous substances, cyclosporine, prednisone, tamox, sirolimus, ...

Embodiment 3

[0050] Chromatographic conditions

[0051]Column: Phenomenex Luna NH 2 (4.6mm×250mm, 5 μm, American Phenomenex Company); mobile phase: acetonitrile-methanol-0.1% trifluoroacetic acid (85:5:10); flow rate: 1.5mL min -1 ; Column temperature: 30°C; Detection wavelength, 280nm.

[0052] Plasma sample pretreatment

[0053] Take 100 μL of plasma sample, add 200 μL of methanol solution, vortex mix for 20 s, centrifuge at 12000×g for 10 min at 4°C, and take 30 μL of supernatant for injection. The external standard method was used to quantify the peak area.

[0054] Exclusive

[0055] Blood samples were taken from 10 kidney transplant patients who did not take MZR, and were determined according to the above-mentioned sample pretreatment and determination methods. In addition, commonly used drug combination and over-the-counter drug reference solution were injected. Results showed endogenous substances, cyclosporine, prednisone, tamox, sirolimus, ganciclovir, betaloc, acetaminophe...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Sensitivityaaaaaaaaaa
linear rangeaaaaaaaaaa
Login to View More

Abstract

The invention relates to an internal drug assay determination method in the field of medical examination, which relates to a method for measuring human plasma imidazole density. It dose equal indicative elution on acid traveling phase condition after doing first treatment to the tested sample by protein depositing and uses ultraviolet detector to test it after chromatographic column separating.

Description

technical field [0001] The invention belongs to the field of medical testing, and relates to an analysis and determination method of drugs in vivo. Specifically relates to a method for measuring the blood concentration of mizoribine. Background technique [0002] Mizoribine (MZR) is a purine nucleoside synthesis inhibitor, which can specifically inhibit the rapid growth of lymphocytes, thereby producing immunosuppressive effects. In recent years, it has been clinically used to suppress rejection during kidney transplantation, and is also used to treat autoimmune diseases such as lupus nephritis, rheumatoid arthritis and nephrotic syndrome. The pharmacokinetics of this drug varies greatly among individuals, and clinically, blood drug concentration monitoring is required to adjust the individualized dosage regimen. [0003] At present, there are only relevant reports abroad about the determination method of MZR in biological samples. Existing technical methods have low sens...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): G01N30/02B01J20/281
Inventor 焦正张明钟明康陆福明
Owner AFFILIATED HUSN HOSPITAL OF FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com